Abstract
Introduction
As the developed markets are becoming increasingly mature, Pharma is turning
to the emerging markets, where long-term growth can be sustained. Of
particular interest are Indonesia and the Philippines, which are currently
going through major reforms to expand their healthcare systems; however there
are key differences between these two markets.
Scope of this research
- Provides a comparative overview of recent events affecting the
macroeconomic and pharmaceutical landscape
- Examines different drivers and resistors for growth in Indonesia and the
Philippines
- Analyzes the growth drivers of multinational and domestic players
operating in these markets
- Identifies key strategies for entry and expansion in these markets
Research and analysis highlights
The global economic downturn has impacted Indonesia, albeit at a lesser extent
than developed countries. Indonesia' s economic prowess has resulted in the
country potentially joining the top tier of emerging markets including Brazil,
Russia, India and China in the near future, as these are to grow at a faster
rate than developed countries.
With the introduction of a single South East Asian market via the free trade
agreement Association of South East Asian Nations (ASEAN) from 2011, in
addition to a full universal insurance coverage in the Philippines and
Indonesia by 2010 and 2013, respectively, the opportunity of pharmaceutical
players to maximize sales will increase.
Domestic pharmaceutical companies in both Indonesia and the Philippines are
ideal M&A targets for multinationals looking to enter or expand in these
markets. This is due to their double digit sales growth, which will be further
fuelled by the growing demand for low cost medicine as healthcare coverage
expands.
Key reasons to purchase this research
- Understand how recent events and trends will affect the pharmaceutical
markets in Indonesia and the Philippines
- Gain insight into which companies are growing rapidly and what strategies
they have employed
- Identify the opportunities and barriers to entering pharma markets in
Indonesia and the Philippines
| 
View Cart
